Table 2 Longitudinal follow-up results of echocardiographic studies.
From: Subtle cardiac dysfunction in lymphoma patients receiving low to moderate dose chemotherapy
Parameters | Total (N = 74) | p* | CTRCD (N = 36) | p* | Non-CTRCD (N = 38) | p* | p# |
|---|---|---|---|---|---|---|---|
LA volume index (mL/m2) | |||||||
Baseline | 26.7 ± 9.0 | 27.4 ± 8.8 | 26.1 ± 9.3 | 0.52 | |||
Post-treatment 3 cycles | 28.8 ± 10.5 | 0.44 | 27.8 ± 11.4 | 0.82 | 28.1 ± 9.8 | 0.38 | 0.90 |
Post-treatment 6 cycles | 27.6 ± 9.8 | 0.69 | 26.4 ± 7.8 | 0.46 | 28.8 ± 11.6 | 0.05 | 0.34 |
Post-treatment 1 year | 28.3 ± 11.0 | 0.89 | 26.0 ± 7.7 | 0.30 | 31.5 ± 13.8 | 0.31 | 0.12 |
LV ESVi (mL/m2) | |||||||
Baseline | 19.2 ± 7.0 | 19.2 ± 7.5 | 19.2 ± 6.6 | 1.00 | |||
Post-treatment 3 cycles | 19.1 ± 9.0 | 0.85 | 19.7 ± 11.1 | 0.64 | 18.5 ± 6.5 | 0.32 | 0.55 |
Post-treatment 6 cycles | 18.4 ± 7.2 | 0.53 | 19.0 ± 8.0 | 0.69 | 17.8 ± 6.5 | 0.16 | 0.49 |
Post-treatment 1 year | 19.7 ± 7.5 | 0.58 | 19.8 ± 6.9 | 0.60 | 19.5 ± 8.3 | 0.82 | 0.89 |
LV EDVi (mL/m2) | |||||||
Baseline | 61.4 ± 14.6 | 62.9 ± 15.1 | 60.1 ± 14.2 | 0.40 | |||
Post-treatment 3 cycles | 62.9 ± 15.7 | 0.34 | 62.4 ± 17.1 | 0.80 | 63.4 ± 14.4 | 0.12 | 0.77 |
Post-treatment 6 cycles | 59.8 ± 14.5 | 0.60 | 60.2 ± 13.4 | 0.45 | 59.4 ± 15.6 | 0.94 | 0.83 |
Post-treatment 1 year | 61.5 ± 14.8 | 0.69 | 60.3 ± 13.1 | 0.42 | 63.2 ± 16.9 | 0.80 | 0.52 |
LVEF (%) | |||||||
Baseline | 69.1 ± 7.0 | 70.2 ± 5.7 | 67.8 ± 7.9 | 0.17 | |||
Post-treatment 3 cycles | 70.1 ± 8.8 | 0.26 | 69.3 ± 10.2 | 0.57 | 71.0 ± 7.3 | < 0.001 | 0.41 |
Post-treatment 6 cycles | 69.5 ± 7.3 | 0.58 | 68.6 ± 8.4 | 0.27 | 70.5 ± 5.9 | 0.03 | 0.31 |
Post-treatment 1 year | 68.5 ± 6.9 | 0.35 | 67.7 ± 6.8 | 0.26 | 69.7 ± 6.9 | 0.99 | 0.33 |
E/A | |||||||
Baseline | 1.0 ± 0.4 | 0.9 ± 0.3 | 1.1 ± 0.5 | 0.13 | |||
Post-treatment 3 cycles | 1.0 ± 0.4 | 0.73 | 1.0 ± 0.4 | 0.44 | 1.0 ± 0.4 | 0.21 | 0.50 |
Post-treatment 6 cycles | 0.9 ± 0.4 | 0.02 | 0.9 ± 0.3 | 0.12 | 1.0 ± 0.4 | 0.09 | 0.09 |
Post-treatment 1 year | 1.1 ± 0.6 | 0.96 | 0.9 ± 0.4 | 0.99 | 1.2 ± 0.8 | 0.95 | 0.12 |
Average E/e′ | |||||||
Baseline | 8.0 ± 3.0 | 8.4 ± 2.7 | 7.7 ± 3.2 | 0.35 | |||
Post-treatment 3 cycles | 8.5 ± 4.1 | 0.26 | 8.9 ± 4.4 | 0.46 | 8.1 ± 3.8 | 0.30 | 0.38 |
Post-treatment 6 cycles | 8.5 ± 3.9 | 0.21 | 8.9 ± 3.8 | 0.33 | 8.1 ± 4.0 | 0.44 | 0.42 |
Post-treatment 1 year | 7.8 ± 3.2 | 0.11 | 7.8 ± 2.1 | 0.35 | 7.8 ± 4.2 | 0.16 | 0.99 |
Absolute value of LV GLS (%) | |||||||
Baseline | 19.7 ± 2.5 | 20.1 ± 2.6 | 19.3 ± 2.2 | 0.16 | |||
Post-treatment 3 cycles | 18.4 ± 2.6 | < 0.001 | 17.5 ± 2.3 | < 0.001 | 19.2 ± 2.6 | 0.68 | 0.01 |
Post-treatment 6 cycles | 17.6 ± 3.0 | < 0.001 | 16.3 ± 2.2 | < 0.001 | 19.6 ± 2.7 | 0.87 | < 0.001 |
Post-treatment 1 year | 18.3 ± 2.4 | < 0.001 | 18.2 ± 2.3 | < 0.001 | 18.5 ± 2.5 | 0.05 | 0.70 |
